Proposed Data Collection Submitted for Public Comment and Recommendations, 27832-27833 [2017-12736]

Download as PDF asabaliauskas on DSKBBXCHB2PROD with NOTICES 27832 Federal Register / Vol. 82, No. 116 / Monday, June 19, 2017 / Notices DGMQ will review a permit application within 3–5 business days of receiving the application and apply the criteria in Federal Register notice published at 79 FR 39403 (July 20, 2014). If the application is approved, a permit will be emailed to the dog’s owner. The owner must present the permit to the Customs and Border Protection (CBP) officer at the first arriving port of entry into the United States. The permit will be collected by the CBP officer and sent to CDC. If the permit application is denied, DGMQ will email the reasons for the denial to the dog’s owner within 3–5 business days of receiving the application. The email will include instructions on whom to contact, including name, address, and telephone number, if the dog’s owner has any questions, as well as information on how to submit an appeal. In accordance with current procedures, individuals who wish to contest CDC’s determination will have five business days after receiving the denial to submit a written appeal. The individual must submit the appeal via email to cdcanimalimports@cdc.gov, state the reasons for the appeal, and show that there is a genuine and substantial issue of fact in dispute. CDC will issue a response via email, which will constitute final agency action. The appeal will be reviewed and decided upon by a CDC senior management official who is senior to the employee who denied the initial permit application. In keeping with current practice, a successful appeal of a denial only permits the owner to import the dog into the United States at a later date under the requirements set forth in a dog import permit. The appeal does not entitle the owner to recover any costs related to returning a dog that has been denied entry to its country of origin and reimporting the dog into the United States. An owner or owner’s agent will not be allowed to board a dog or arrange for its confinement at a port of entry pending a determination regarding the importer’s application to import an inadequately immunized dog. Accordingly, inadequately immunized dogs arriving at a port of entry without an approved permit will be denied entry into the United States and re-exported to its country of origin at the owner’s expense. III. Paperwork Reduction Act This change does not institute a new collection of information. The collection of information, has been previously approved by the Office of Management and Budget (OMB) in accordance with the requirements of the Paperwork VerDate Sep<11>2014 17:09 Jun 16, 2017 Jkt 241001 Reduction Act (44 U.S.C. 3507) and assigned the following OMB control number: Foreign Quarantine: OMB Control No. 0920–0134, expiration date 5/31/2019. Dated: June 12, 2017. Sandra Cashman, Executive Secretary, Centers for Disease Control and Prevention. [FR Doc. 2017–12439 Filed 6–16–17; 8:45 am] BILLING CODE 4163–18–P Docket Number. All relevant comments received will be posted without change to Regulations.gov, including any personal information provided. For access to the docket to read background documents or comments received, go to Regulations.gov. Please note: All public comment should be submitted through the Federal eRulemaking portal (Regulations.gov) or by U.S. mail to the address listed above. To request more information on the proposed project or to obtain a copy of the information collection plan and instruments, contact Leroy A. Richardson, Information Collection Review Office, Centers for Disease Control and Prevention, 1600 Clifton Road, NE., MS–D74, Atlanta, Georgia 30329; phone: 404–639–7570; Email: omb@cdc.gov. SUPPLEMENTARY INFORMATION: Under the Paperwork Reduction Act of 1995 (PRA) (44 U.S.C. 3501–3520), Federal agencies must obtain approval from the Office of Management and Budget (OMB) for each collection of information they conduct or sponsor. In addition, the PRA also requires Federal agencies to provide a 60-day notice in the Federal Register concerning each proposed collection of information, including each new proposed collection, each proposed extension of existing collection of information, and each reinstatement of previously approved information collection before submitting the collection to OMB for approval. To comply with this requirement, we are publishing this notice of a proposed data collection as described below. Comments are invited on: (a) Whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency’s estimate of the burden of the proposed collection of information; (c) ways to enhance the quality, utility, and clarity of the information to be collected; (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology; and (e) estimates of capital or start-up costs and costs of operation, maintenance, and purchase of services to provide information. Burden means the total time, effort, or financial resources expended by persons to generate, maintain, retain, disclose or provide information to or for a Federal agency. This includes the time needed to review instructions; to develop, acquire, install and utilize technology FOR FURTHER INFORMATION CONTACT: DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention [60Day–17–17ACE; Docket No. CDC–2017– 0043] Proposed Data Collection Submitted for Public Comment and Recommendations Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS). ACTION: Notice with comment period. AGENCY: The Centers for Disease Control and Prevention (CDC), as part of its continuing efforts to reduce public burden and maximize the utility of government information, invites the general public and other Federal agencies to take this opportunity to comment on proposed and/or continuing information collections, as required by the Paperwork Reduction Act of 1995. This notice invites comment on a proposed information collection entitled ‘‘Evaluation of Medication-Assisted Treatment (MAT) for Opioid use disorder.’’ CDC will use the collection to conduct an epidemiologic study to assess the type of MAT (methadone maintenance; buprenorphine; naltrexone; or, counseling, no MAT), and the contextual, provider, and individual factors that influence implementation and improved patient wellbeing over a two-year follow up period. DATES: Written comments must be received on or before August 18, 2017. ADDRESSES: You may submit comments, identified by Docket No. CDC–2017– 0043 by any of the following methods: • Federal eRulemaking Portal: Regulations.gov. Follow the instructions for submitting comments. • Mail: Leroy A. Richardson, Information Collection Review Office, Centers for Disease Control and Prevention, 1600 Clifton Road NE., MS– D74, Atlanta, Georgia 30329. Instructions: All submissions received must include the agency name and SUMMARY: PO 00000 Frm 00051 Fmt 4703 Sfmt 4703 E:\FR\FM\19JNN1.SGM 19JNN1 27833 Federal Register / Vol. 82, No. 116 / Monday, June 19, 2017 / Notices and systems for the purpose of collecting, validating and verifying information, processing and maintaining information, and disclosing and providing information; to train personnel and to be able to respond to a collection of information, to search data sources, to complete and review the collection of information; and to transmit or otherwise disclose the information. Proposed Project Evaluation of Medication-Assisted Treatment (MAT) for Opioid use disorder—New—National Center for Injury Prevention and Control (NCIPC), Centers for Disease Control and Prevention (CDC). Background and Brief Description CDC seeks a three-year OMB approval to collect evaluation information for Medication-Assisted Treatment (MAT) for Opioid use disorder. About 2.4 million people aged 18 or older have opioid use disorders (OUDs) real-world outpatient settings. The study aims to have 3,000 participants from real-world outpatient settings to better understand the relationship between type of MAT and individual, provider, and contextual characteristics related to retention in treatment and abstinence from opioid use. The sites will be located across 10 diverse metropolitan statistical areas (MSAs) with four sites in each MSA. At each site, about 75 participants are expected to participate for a total of 300 per MSA. Across all MSAs, the study will aim to have 750 client participants in each of the four treatment conditions (MMT, BUP, NAL, and COUN). The study will use a mixed-method approach using quantitative methods such as multilevel latent growth models, propensity score matching, latent class analysis and advance mediation analysis and qualitative methods such as interactive coding and analysis for common themes. The only cost to respondents will be time spent responding to the survey/screener. in the United States. At any given time, only half of these people receive some form of treatment, which may include medication-assisted treatment (MAT) or abstinence-based psychotherapy or selfhelp treatments (i.e., counseling without medication [COUN]). The rise in opioid overdose deaths, up from 2014–2015 due partly to a 72% rise in synthetic opioid overdose deaths alone, shows that engaging and retaining clients in OUD treatment is an urgent public health need. Only a few studies are available to help clients and providers make informed decisions about the risks and benefits associated with the different types of MATs. This information is crucial because even though each MAT drug helps prevent withdrawal symptoms and decreases cravings, differences in treatment approach and settings influence how people respond to the medication and, thus, their long-term treatment success. The purpose of this evaluation is to conduct an epidemiologic, mixedmethods evaluation of OUD treatment in ESTIMATED ANNUALIZED BURDEN HOURS Number of respondents Type of respondents Instrument name Provider site staff .............................. Client Permission Form .................... Visit Form ......................................... Site Director Questionnaire .............. Focus Groups ................................... Client Screener ................................ Client Check-in ................................. Client Questionnaire ......................... Focus Groups ................................... Client respondents ............................ Number of responses per respondent 15 15 15 27 1,333 1,000 2,412 27 100 525 2 1 1 2 1 1 Total ........................................... Leroy A. Richardson, Chief, Information Collection Review Office, Office of Scientific Integrity, Office of the Associate Director for Science, Office of the Director, Centers for Disease Control and Prevention. [FR Doc. 2017–12736 Filed 6–16–17; 8:45 am] BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES asabaliauskas on DSKBBXCHB2PROD with NOTICES Administration for Children and Families Proposed Information Collection Activity; Comment Request Title: Administration for Native Americans Objective Work Plan (OWP) and Objective Progress Report (OPR). OMB No.: 0970–0452. Description: Content and formatting changes are being made to the VerDate Sep<11>2014 17:09 Jun 16, 2017 Jkt 241001 Administration for Native Americans’ (ANA) Objective Work Plan (OWP) and Objective Progress Report (OPR). The OWP is used by applicants when they submit their proposals and then by grantees to monitor their projects once the award is made by ANA. Slight content changes are proposed for the OWP approved under information collection OMB No. 0970–0452, Expiration Date 6/30/2018. An extension of expiration date is also requested. This will streamline the information collection and reduce the number of elements. OWP: The following are proposed content changes to the document: ANA proposes to eliminate Problem Statement and Results and Benefits and Criteria for Evaluation of results and benefits from the OWP. These elements will no longer be required by applicants for ANA discretionary grants. ANA will PO 00000 Frm 00052 Fmt 4703 Sfmt 4703 Average burden per response (hours) 5/60 10/60 1 90/60 5/60 15/60 49/60 90/60 Total burden (hours) 125 1,313 30 41 111 500 1,978 41 4,139 consolidate staffing into one field for both lead and support staff. ANA will require applicants to differentiate between administrative activities and milestone activities. Administrative activities are those directly related to grant administration, such as reporting and attending postaward training. Milestone activities are key activities needed to complete project objectives. These activities may result in a single output; therefore ANA will require applicants to identify outputs related to milestone activities as necessary. OPR: Currently, ANA requires grantees to report on the status of results and benefits in the OPR. This section will be deleted as ANA no longer requires grantees to identify results or benefits from their project, just outcomes. Outcomes will be reported annually in a separate OMB approved form. E:\FR\FM\19JNN1.SGM 19JNN1

Agencies

[Federal Register Volume 82, Number 116 (Monday, June 19, 2017)]
[Notices]
[Pages 27832-27833]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-12736]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[60Day-17-17ACE; Docket No. CDC-2017-0043]


Proposed Data Collection Submitted for Public Comment and 
Recommendations

AGENCY: Centers for Disease Control and Prevention (CDC), Department of 
Health and Human Services (HHS).

ACTION: Notice with comment period.

-----------------------------------------------------------------------

SUMMARY: The Centers for Disease Control and Prevention (CDC), as part 
of its continuing efforts to reduce public burden and maximize the 
utility of government information, invites the general public and other 
Federal agencies to take this opportunity to comment on proposed and/or 
continuing information collections, as required by the Paperwork 
Reduction Act of 1995. This notice invites comment on a proposed 
information collection entitled ``Evaluation of Medication-Assisted 
Treatment (MAT) for Opioid use disorder.'' CDC will use the collection 
to conduct an epidemiologic study to assess the type of MAT (methadone 
maintenance; buprenorphine; naltrexone; or, counseling, no MAT), and 
the contextual, provider, and individual factors that influence 
implementation and improved patient wellbeing over a two-year follow up 
period.

DATES: Written comments must be received on or before August 18, 2017.

ADDRESSES: You may submit comments, identified by Docket No. CDC-2017-
0043 by any of the following methods:
     Federal eRulemaking Portal: Regulations.gov. Follow the 
instructions for submitting comments.
     Mail: Leroy A. Richardson, Information Collection Review 
Office, Centers for Disease Control and Prevention, 1600 Clifton Road 
NE., MS-D74, Atlanta, Georgia 30329.
    Instructions: All submissions received must include the agency name 
and Docket Number. All relevant comments received will be posted 
without change to Regulations.gov, including any personal information 
provided. For access to the docket to read background documents or 
comments received, go to Regulations.gov.

    Please note: All public comment should be submitted through the 
Federal eRulemaking portal (Regulations.gov) or by U.S. mail to the 
address listed above.


FOR FURTHER INFORMATION CONTACT: To request more information on the 
proposed project or to obtain a copy of the information collection plan 
and instruments, contact Leroy A. Richardson, Information Collection 
Review Office, Centers for Disease Control and Prevention, 1600 Clifton 
Road, NE., MS-D74, Atlanta, Georgia 30329; phone: 404-639-7570; Email: 
omb@cdc.gov.

SUPPLEMENTARY INFORMATION: Under the Paperwork Reduction Act of 1995 
(PRA) (44 U.S.C. 3501-3520), Federal agencies must obtain approval from 
the Office of Management and Budget (OMB) for each collection of 
information they conduct or sponsor. In addition, the PRA also requires 
Federal agencies to provide a 60-day notice in the Federal Register 
concerning each proposed collection of information, including each new 
proposed collection, each proposed extension of existing collection of 
information, and each reinstatement of previously approved information 
collection before submitting the collection to OMB for approval. To 
comply with this requirement, we are publishing this notice of a 
proposed data collection as described below.
    Comments are invited on: (a) Whether the proposed collection of 
information is necessary for the proper performance of the functions of 
the agency, including whether the information shall have practical 
utility; (b) the accuracy of the agency's estimate of the burden of the 
proposed collection of information; (c) ways to enhance the quality, 
utility, and clarity of the information to be collected; (d) ways to 
minimize the burden of the collection of information on respondents, 
including through the use of automated collection techniques or other 
forms of information technology; and (e) estimates of capital or start-
up costs and costs of operation, maintenance, and purchase of services 
to provide information. Burden means the total time, effort, or 
financial resources expended by persons to generate, maintain, retain, 
disclose or provide information to or for a Federal agency. This 
includes the time needed to review instructions; to develop, acquire, 
install and utilize technology

[[Page 27833]]

and systems for the purpose of collecting, validating and verifying 
information, processing and maintaining information, and disclosing and 
providing information; to train personnel and to be able to respond to 
a collection of information, to search data sources, to complete and 
review the collection of information; and to transmit or otherwise 
disclose the information.

Proposed Project

    Evaluation of Medication-Assisted Treatment (MAT) for Opioid use 
disorder--New--National Center for Injury Prevention and Control 
(NCIPC), Centers for Disease Control and Prevention (CDC).

Background and Brief Description

    CDC seeks a three-year OMB approval to collect evaluation 
information for Medication-Assisted Treatment (MAT) for Opioid use 
disorder.
    About 2.4 million people aged 18 or older have opioid use disorders 
(OUDs) in the United States. At any given time, only half of these 
people receive some form of treatment, which may include medication-
assisted treatment (MAT) or abstinence-based psychotherapy or self-help 
treatments (i.e., counseling without medication [COUN]). The rise in 
opioid overdose deaths, up from 2014-2015 due partly to a 72% rise in 
synthetic opioid overdose deaths alone, shows that engaging and 
retaining clients in OUD treatment is an urgent public health need. 
Only a few studies are available to help clients and providers make 
informed decisions about the risks and benefits associated with the 
different types of MATs. This information is crucial because even 
though each MAT drug helps prevent withdrawal symptoms and decreases 
cravings, differences in treatment approach and settings influence how 
people respond to the medication and, thus, their long-term treatment 
success.
    The purpose of this evaluation is to conduct an epidemiologic, 
mixed-methods evaluation of OUD treatment in real-world outpatient 
settings. The study aims to have 3,000 participants from real-world 
outpatient settings to better understand the relationship between type 
of MAT and individual, provider, and contextual characteristics related 
to retention in treatment and abstinence from opioid use. The sites 
will be located across 10 diverse metropolitan statistical areas (MSAs) 
with four sites in each MSA. At each site, about 75 participants are 
expected to participate for a total of 300 per MSA. Across all MSAs, 
the study will aim to have 750 client participants in each of the four 
treatment conditions (MMT, BUP, NAL, and COUN).
    The study will use a mixed-method approach using quantitative 
methods such as multilevel latent growth models, propensity score 
matching, latent class analysis and advance mediation analysis and 
qualitative methods such as interactive coding and analysis for common 
themes. The only cost to respondents will be time spent responding to 
the survey/screener.

                                        Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
                                                                     Number of    Average burden
      Type of respondents        Instrument name     Number of     responses per   per response    Total burden
                                                    respondents     respondent        (hours)         (hours)
----------------------------------------------------------------------------------------------------------------
Provider site staff...........  Client                        15             100            5/60             125
                                 Permission Form.
                                Visit Form......              15             525           10/60           1,313
                                Site Director                 15               2               1              30
                                 Questionnaire.
                                Focus Groups....              27               1           90/60              41
Client respondents............  Client Screener.           1,333               1            5/60             111
                                Client Check-in.           1,000               2           15/60             500
                                Client                     2,412               1           49/60           1,978
                                 Questionnaire.
                                Focus Groups....              27               1           90/60              41
    Total.....................                                                                             4,139
----------------------------------------------------------------------------------------------------------------


Leroy A. Richardson,
Chief, Information Collection Review Office, Office of Scientific 
Integrity, Office of the Associate Director for Science, Office of the 
Director, Centers for Disease Control and Prevention.
[FR Doc. 2017-12736 Filed 6-16-17; 8:45 am]
BILLING CODE 4163-18-P